Visiongain Publishes Protein Engineering Market Report 2021-2031

15 February 2021
Pharma

Visiongain has published a new report on Protein Engineering Market Report 2021-2031: Forecasts by Product (Consumables, Instruments, Software & Services), by Protein Type (Monoclonal Antibodies, Insulin, Vaccines, Erythropoietins, Colony-Stimulating Factors, Growth Hormones, Coagulation Factors, Interferons, Other Proteins), by Technology (Rational Protein Design, Irrational Protein Design, Hybrid Protein Design), by End-User (Biopharmaceutical Companies, Contract Research Organisations, Academic Research Institutes) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Protein Engineering Companies AND COVID-19 Recovery Scenarios.

Global protein engineering market was valued at US$ xx million in 2020 and is projected to reach at a market value of US$ xx million by 2031. Growing investment in drug R&D by pharmaceutical and biopharmaceutical companies; investment by government for novel vaccine development for COVID-19; rising prevalence of autoimmune diseases; mounting demand for biologics & biosimilars; and developing healthcare infrastructure in emerging economies are some of the major factors that propel the market growth.

COVID-19 Impact on Protein Engineering Market
The spread of coronavirus has contributed to an increase in the number of research activities to establish a vaccine to treat and prevent infection among healthy people. Several manufacturers of vaccines around the world have expanded their testing ability to find an effective coronavirus vaccine. Higher vaccine demand is expected to place pressure on manufacturers and healthcare professionals to supply the vaccine. The increasing number of funding to encourage immunisation and product development by government and private organisations are the key drivers of the demand for protein engineering.

Market Drivers
The growing demand for biosimilars is expected to boost the demand of protein engineering products. Thus, demand for the protein engineering products for the development and manufacturing of biosimilar drugs is high. Over the past few years, knowledge and acceptance of biosimilars has increased, resulting in a booming protein engineering market.

The escalating demand for contract research services for drugs and biologics R&D is another major factor driving the market growth. The biopharmaceutical industry’s aspiration to tap opportunities in developing economies is reshaping the market. Minimizing investment in R&D facilities can free up company resources that can be utilized in other areas including manufacturing and marketing.

Market Opportunities
There is a high demand for more efficient and reliable biologics and biosimilars for the treatment and maintenance of chronic diseases. An increase in the R&D investment by biologics companies and research institutes is a major factor that boosts the demand for protein engineering products worldwide. The consistent investments being made by companies around the world for developing biologics for the treatment of chronic diseases, therefore the adoption of protein engineering for drug R&D is expected to increase over the coming decade.

The biotechnology companies are offering advanced products and technology for the development of vaccines. Thus, the demand for protein engineering will also increase for the development and manufacturing of vaccines for the COVID-19 immunization programs worldwide. The manufacturers are focusing on the production of these products to cater to the expected high demand in the near future that is expected to boost the market growth.

Competitive Landscape
Protein engineering market is a highly competitive market with several global and local players. Some of the leading players in this market include Thermo Fisher Scientific, Inc.; Danaher Corporation; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Bruker Corporation; Merck KGaA; Perkinelmer, Inc.; Cytiva; Promega Corporation; Takara Bio, Inc.; Genscript Biotech Corporation; Codexis, Inc.; New England Biolabs, Inc.; Creative Biolabs; Phynexus, Inc.

The major strategies acquired by the leading players are collaborations, M&A, high investment in R&D, new product launches, and geographical expansion. These strategies help the companies to reinforce their existing product portfolio and regional reach. For instance, in November 2020, Perkinelmer announces that it will acquire Horizon Discovery, which is a cell engineering company for US$383 million.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever